三种方案治疗消化性溃疡的成本-效果分析  

A Cost-effect Analysis of Three Therapeutic Schemes for Helicobacter Pylori Positive Peptic Ulcer

作　　者：陈敏玲[1] 张顺国[1] 毛五妹[1] 

机构地区：[1]上海第二医科大学附属新华医院药剂科,200092

出　　处：《医药导报》2001年第12期743-744,共2页Herald of Medicine

摘　　要：目的 :探讨不同的药物治疗方案对幽门螺杆菌 (Hp)感染的消化性溃疡所产生的经济效果。方法 :160例患者随机分为三组 :A组 5 8例 ,治疗方法为枸橼酸铋钾 0 .2 2g +克拉霉素 0 .2 5g +替硝唑 0 .5g ,po,bid× 7d ;B组 5 0例 ,治疗方法同A组 ,疗程为 14d ;C组 5 2例 ,治疗方案为奥美拉唑 2 0mg +甲硝唑 4 0 0mg +阿莫西林 1g ,po ,bid× 7d。运用经济学成本 效果分析对三种治疗方案进行分析评价。结果 :三种方案的成本 效果比 (C/E)分别为 10 .5 2 ,12 .74 ,11.70。结论Objective: To evaluate the economic effect of different pharmacotherapeutic schemes for helicobacter pylove positive peptic ulcer. Methods:160 patients with helicobacter pylori positive peptic ulcer were randomly divided into 3 groups. 58 patients were treated with the scheme A: bismuth potassium citrate 0.22 g+clarithromycin 0.25 g+tinidazole 0.5 g, po, b.i.d.×7 d; 50 patients were treated according to the scheme B: the same as scheme A except for that the course of treatment lasted 14d. 52 patients were treated according to the scheme C: omeprazole 20 mg+metronidazole 400 mg+amoxicillin 1 g, po, b.i.d.×7 d. The three therapeutic schemes A,B, and C were evaluated with pharmacoeconomic cost effect analysis. Results:The cost effect ratios of the three therapeutic schemes A,B and C were 10.52, 12.74, and 11.70 respectively. Conclusion: The scheme A is the best one.

关 键 词：幽门螺杆菌 消化性溃疡 药物经济学 成本-效果分析 

分 类 号：R573.1[医药卫生—消化系统] R975.6[医药卫生—内科学]